Bosutinib - an effective and safe treatment option in the management of chronic myeloid leukemia

被引：3
|
作者：
Ercaliskan, Abdulkadir [1 ]
Eskazan, Ahmet Emre [1 ]
机构：
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Div Hematol, Dept Internal Med, TR-34303 Istanbul, Turkey
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 03期
关键词：
adverse event; bosutinib; chronic myeloid leukemia; comorbidity; imatinib; tyrosine kinase inhibitor; KINASE INHIBITOR TKI; IMATINIB; DASATINIB; DISCONTINUATION; NILOTINIB; THERAPY; CML;
D O I：
10.2217/fon-2020-0006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4425 / 4428
页数：4
相关论文
共 50 条
  • [21] Recent progress in the management of pediatric chronic myeloid leukemia
    Shima, Haruko
    Shimada, Hiroyuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (02) : 182 - 187
  • [22] Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia
    Hill, Brittany G.
    Kota, Vamsi K.
    Khoury, Hanna Jean
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (07) : 765 - 770
  • [23] Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
    Takahashi, Naoto
    Cortes, Jorge E.
    Sakaida, Emiko
    Ishizawa, Kenichi
    Ono, Takaaki
    Doki, Noriko
    Matsumura, Itaru
    Garcia-Gutierrez, Valentin
    Rosti, Gianantonio
    Ono, Chiho
    Ohkura, Masayuki
    Tanetsugu, Yusuke
    Viqueira, Andrea
    Brummendorf, Tim H.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (06) : 838 - 851
  • [24] The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective
    Agarwal, Mohan Bajranglal
    John, Manthanathu Joseph
    Jain, Punit
    Vaid, Ashok Kumar
    Bapna, Ajay
    Basade, Maheboob
    Dattatreya, Palanki Satya
    Chakrapani, Anupam
    Ramanan, Vijay
    Varadarajan, R.
    Subramanian, Murali
    Shah, Chirag Aniruddha
    Warrier, Narayanakutty
    Sanyal, Subhaprakash
    Ashwin, Tyavanagi Shankarmurthy
    Ramanjinappa, Nagendra
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2024, 45 (04) : 279 - 285
  • [25] Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment
    Takahashi, Naoto
    Nakaseko, Chiaki
    Kobayashi, Yukio
    Miyamura, Koichi
    Ono, Chiho
    Koide, Yuichiro
    Fujii, Yosuke
    Ohnishi, Kazunori
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (03) : 398 - 410
  • [26] Ever-advancing chronic myeloid leukemia treatment
    Kimura, Shinya
    Ando, Toshihiko
    Kojima, Kensuke
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (01) : 3 - 9
  • [27] Treatment options for chronic myeloid leukemia
    Tanaka, Maria Florencia
    Kantarjian, Hagop
    Cortes, Jorge
    Ohanian, Maro
    Jabbour, Elias
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (06) : 815 - 828
  • [28] Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia
    Keller-v. Amsberg, Gunhild
    Bruemmendorf, Tim H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1121 - 1127
  • [29] An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Leip, Eric
    Viqueira, Andrea
    Heeg, Bart
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (05) : 801 - 809
  • [30] Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia
    Rao, Kamakshi V.
    Iannucci, Andrea
    Jabbour, Elias
    PHARMACOTHERAPY, 2010, 30 (09): : 77S - 101S
12345